http://tan.sagepub.com/content/5/5/255.abstract?etoc=
Abstract
A large proportion of patients with
multiple sclerosis (MS) have spasticity, which has a marked impact on
their quality of
life. Anecdotal evidence suggests a beneficial
effect of cannabis on spasticity as well as pain. Recently, randomized,
double-blind,
placebo-controlled studies have confirmed the
clinical efficacy of cannabinoids for the treatment of spasticity in
patients
with MS. Based on these data, nabiximols (Sativex),
a 1:1 mix of Δ-9-tetrahydrocannabinol and cannabidiol extracted from
cloned
Cannabis sativa chemovars, received
approval for treating MS-related spasticity in various countries around
the globe. In this article we
review the current understanding of cannabinoid
biology and the value of cannabinoids as a symptomatic treatment option
addressing
spasticity in patients with MS.
No comments:
Post a Comment